Table 1. Comparisons of body weight and plasma parameters in WT, vehicle- or febuxostat-treated ApoE−/− mice.
| WT | ApoE−/− | ApoE−/− | |
|---|---|---|---|
| Parameters | Vehicle | Vehicle | Febuxostat |
| BW (g) | 29.3 ± 0.4 | 36.1 ± 1.6† | 37.5 ± 0.9* |
| T chol (mg/dL) | 69.2 ± 2.8 | 1499.8 ± 46.6* | 1406.0 ± 90.8* |
| HDL (mg/dL) | 42.0 ± 2.1 | 10.8 ± 1.2* | 14.4 ± 1.0§* |
| TG (mg/dL) | 74.8 ± 9.7 | 165.8 ± 17.9† | 204.6 ± 20.9* |
| NEFA (mg/dL) | 405.6 ± 31.0 | 698.6 ± 55.6† | 681.8 ± 46.4† |
| Glucose (mg/dL) | 202.6 ± 7.2 | 237.4 ± 9.3‡ | 246.8 ± 7.5† |
| XO activity (mU/mL) | 62.3 ± 1.8 | 87.4 ± 1.9* | 54.9 ± 3.9|| |
Plasma was prepared after 12 weeks from vehicle-treated WT mice or from vehicle- or febuxostat-treated ApoE−/− mice. Values are mean ± SEM. BW indicates body weight; T chol, total cholesterol; HDL, high density lipoprotein; TG, triacylglycerol; NEFA, non-esterified fatty acid. XOR activity in plasma was derived from XO, but not XDH. Samples numbers: n = 20 for XO activity and n = 10 for the other parameters.
*P < 0.0001;
†P < 0.001;
‡P < 0.01 vs. WT;
§P < 0.05;
||P < 0.0001 vs. vehicle-treated ApoE−/− mice.